favorites

CSL prepares to slash R&D as it grapples with looming Trump tariffs

The market is focused on a mooted 200 per cent levy on the pharmaceutical giant’s goods. There are far more significant changes afoot at the company.

Michael Smith

The state has outlawed private hospitals running acute wards – and the private hospital giant wants to hand over its facility. But no deal is...

The value of West Australian nerve repair biotech Orthocell has doubled since September as it beefs up its shareholder bases and prepares to break...

They’re under fire from parliamentarians and hospitals for making too much profit, and yet are caught in a customer land grab that is shaving away...